Posted on 30/11/2009 in Pharmaceutical Company Product News Ipsen has announced the start of a trial into its investigational first-in-class steroid sulfatase (STS) inhibitor BN83495.
The drug's ability to treat advanced endometrial cancer will be examined in the controlled international, multi-centre randomised study.
BN83495 - a first-in-class orally available irreversible (STS) inhibitor - gives rise to oestrone and dehydroepiandrosterone that produce oestradiol and androstenediol that can stimulate the growth of hormone-dependent tumours.
"With further indications in breast, prostate and ovarian cancers, we believe Ipsen - with its focus on hormone-dependent cancers - will fully leverage the value of BN83495," explained Stephane Thiroloix, executive vice-president of corporate development with the organisation.
In other Ipsen news, the firm announced earlier this month that it received approval for the marketing of decapeptyl (triptorelin embonate) for the treatment of locally advanced and metastatic prostate cancer.
Authorisation was granted by the Agence Francaise de Securite Sanitaire des Produits de Sante and concerns a six-month sustained-release formulation.Other news stories from 30/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
